These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2176616)

  • 1. Studies on the structural requirement for ligand binding to the neuropeptide Y (NPY) receptor from rat cerebral cortex.
    Baeza CR; Undén A
    FEBS Lett; 1990 Dec; 277(1-2):23-5. PubMed ID: 2176616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative structural requirements of brain neuropeptide Y binding sites and vas deferens neuropeptide Y receptors.
    Martel JC; Fournier A; St-Pierre S; Dumont Y; Forest M; Quirion R
    Mol Pharmacol; 1990 Oct; 38(4):494-502. PubMed ID: 2172766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional effects and ligand binding of chimeric galanin-neuropeptide Y (NPY) peptides on NPY and galanin receptor types.
    Kahl U; Langel U; Bartfai T; Grundemar L
    Br J Pharmacol; 1994 Apr; 111(4):1129-34. PubMed ID: 7518295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide-YY and neuropeptide-Y inhibit vasoactive intestinal peptide-stimulated adenosine 3',5'-monophosphate production in rat small intestine: structural requirements of peptides for interacting with peptide-YY-preferring receptors.
    Servin AL; Rouyer-Fessard C; Balasubramaniam A; Saint Pierre S; Laburthe M
    Endocrinology; 1989 Feb; 124(2):692-700. PubMed ID: 2536315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropeptide Y N-terminal deletion fragments: correlation between solution structure and receptor binding activity at Y1 receptors in rat brain cortex.
    Hu L; Balse P; Doughty MB
    J Med Chem; 1994 Oct; 37(21):3622-9. PubMed ID: 7932589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-helical small molecular size analogues of neuropeptide Y: structure-activity relationships.
    Jung G; Beck-Sickinger AG; Dürr H; Gaida W; Schnorrenberg G
    Biopolymers; 1991 May; 31(6):613-9. PubMed ID: 1657233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly potent and small neuropeptide Y agonist obtained by linking NPY 1-4 via spacer to alpha-helical NPY 25-36.
    Beck A; Jung G; Gaida W; Köppen H; Lang R; Schnorrenberg G
    FEBS Lett; 1989 Feb; 244(1):119-22. PubMed ID: 2538345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure/activity relationships of C-terminal neuropeptide Y peptide segments and analogues composed of sequence 1-4 linked to 25-36.
    Beck-Sickinger AG; Jung G; Gaida W; Köppen H; Schnorrenberg G; Lang R
    Eur J Biochem; 1990 Dec; 194(2):449-56. PubMed ID: 2176597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropeptide Y: Y1 and Y2 affinities of the complete series of analogues with single D-residue substitutions.
    Kirby DA; Boublik JH; Rivier JE
    J Med Chem; 1993 Nov; 36(24):3802-8. PubMed ID: 8254609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropeptide Y (NPY) metabolism by endopeptidase-2 hinders characterization of NPY receptors in rat kidney.
    Price JS; Kenny AJ; Huskisson NS; Brown MJ
    Br J Pharmacol; 1991 Oct; 104(2):321-6. PubMed ID: 1665730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic desipramine treatment reduces regional neuropeptide Y binding to Y2-type receptors in rat brain.
    Widdowson PS; Halaris AE
    Brain Res; 1991 Jan; 539(2):196-202. PubMed ID: 1647239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinction of NPY receptors in vitro and in vivo. I. NPY-(18-36) discriminates NPY receptor subtypes in vitro.
    Michel MC; Schlicker E; Fink K; Boublik JH; Göthert M; Willette RN; Daly RN; Hieble JP; Rivier JE; Motulsky HJ
    Am J Physiol; 1990 Jul; 259(1 Pt 1):E131-9. PubMed ID: 2164786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific neuropeptide Y binding sites in chicken brain.
    Adamo ML; Hazelwood RL
    Am J Physiol; 1991 Jun; 260(6 Pt 1):E839-45. PubMed ID: 1647670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropeptide Y1 subtype pharmacology of a recombinantly expressed neuropeptide receptor.
    Krause J; Eva C; Seeburg PH; Sprengel R
    Mol Pharmacol; 1992 May; 41(5):817-21. PubMed ID: 1316999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel cyclic analog of neuropeptide Y specific for the Y2 receptor.
    Beck-Sickinger AG; Grouzmann E; Hoffmann E; Gaida W; van Meir EG; Waeber B; Jung G
    Eur J Biochem; 1992 Jun; 206(3):957-64. PubMed ID: 1318842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationship of novel pentapeptide neuropeptide Y receptor antagonists is consistent with a noncontinuous epitope for ligand-receptor binding.
    Daniels AJ; Matthews JE; Viveros OH; Leban JJ; Cory M; Heyer D
    Mol Pharmacol; 1995 Sep; 48(3):425-32. PubMed ID: 7565622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solution structure by 2D 1H-NMR of a chimeric peptide recognized by galanin and neuropeptide Y receptors.
    Arvidsson K; Land T; Langel U; Bartfai T; Ehrenberg A
    Biochemistry; 1993 Aug; 32(30):7787-98. PubMed ID: 7688568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orthogonal solid-phase synthesis of a monobiotinylated analog of neuropeptide Y.
    Rivera Baeza C; Undén A
    Int J Pept Protein Res; 1992 Mar; 39(3):195-200. PubMed ID: 1399257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of receptor antagonists of neuropeptide Y.
    Tatemoto K; Mann MJ; Shimizu M
    Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1174-8. PubMed ID: 1311083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of positions in the human neuropeptide Y/peptide YY receptor Y2 that contribute to pharmacological differences between receptor subtypes.
    Fällmar H; Åkerberg H; Gutiérrez-de-Terán H; Lundell I; Mohell N; Larhammar D
    Neuropeptides; 2011 Aug; 45(4):293-300. PubMed ID: 21696823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.